Autolus Therapeutics (NASDAQ:AUTL) Upgraded by Wall Street Zen to Sell Rating

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Several other equities analysts have also weighed in on AUTL. Weiss Ratings upgraded shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Mizuho reduced their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. HC Wainwright increased their price target on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock opened at $1.56 on Friday. Autolus Therapeutics has a fifty-two week low of $1.18 and a fifty-two week high of $2.70. The stock has a market cap of $415.21 million, a PE ratio of -1.43 and a beta of 2.02. The firm’s 50-day simple moving average is $1.57 and its 200 day simple moving average is $1.55.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The business had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. As a group, analysts predict that Autolus Therapeutics will post -0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Independent Advisor Alliance bought a new position in Autolus Therapeutics in the 4th quarter worth approximately $28,000. Marex Group plc purchased a new position in Autolus Therapeutics in the 2nd quarter valued at approximately $28,000. Waverly Advisors LLC purchased a new position in Autolus Therapeutics in the 1st quarter valued at approximately $37,000. SmartHarvest Portfolios LLC purchased a new position in Autolus Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Autolus Therapeutics in the 3rd quarter valued at approximately $46,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.